FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308179007> ?p ?o ?g. }

• W4308179007 endingPage "e003522" @default.
• W4308179007 startingPage "e003522" @default.
• W4308179007 abstract "Feline leukemia virus (FeLV) infection was discovered over 50 years ago; however, the serious clinical changes associated with FeLV infection still have great importance in the diagnosis, prevention, and clinical management of symptomatic patients. Progressive infection with FeLV leads to a reduction in the patient's life expectancy and quality of life. This report describes the use of an antiretroviral integrase inhibitor, raltegravir, in two cats with natural FeLV infection. Raltegravir was administered orally at a dose of 40 mg/cat every 12 h in both cases. In case one, 13 weeks after starting raltegravir, RNA loads were undetectable, while proviral DNA loads were still detectable. In case two, proviral DNA loads were undetectable after 32 weeks of medication, while RNA loads were undetectable throughout the treatment. No adverse effects or laboratory test abnormalities were detected with the use of raltegravir in either patient. The patients are currently clinically healthy, still receiving the drug, and are under close observation. To our knowledge, this is the first report describing the use of raltegravir in naturally infected FeLV-positive cats and its effects on circulating viral load. Moreover, the patients described here were followed-up for a longer period than those in previously reported cases.A infecção pelo vírus da leucemia felina foi descoberta há mais de 50 anos, mas as graves alterações clínicas associadas à infecção pelo FeLV, ainda denotam grande importância no diagnóstico, nas medidas de prevenção e no manejo clínico de pacientes sintomáticos. A infecção progressiva pelo FeLV acarreta na redução do tempo e qualidade de vida do paciente. Este relato descreve o uso de um antirretroviral inibidor da integrase, o raltegravir, em dois gatos com infecção natural pelo FeLV. O raltegravir foi utilizado na dose de 40 mg/gato por via oral a cada 12 horas em ambos os casos. No primeiro caso após treze semanas do uso do raltegravir, a quantificação de RNA foi indetectável e no segundo caso, após trinta e duas semanas o número de cópias de DNA pró-viral foi indetectável. A carga de RNA nunca foi detectada neste paciente. Nenhum efeito adverso, nem alterações laboratoriais foram detectadas com o uso do raltegravir em ambos os casos. Atualmente, os pacientes encontram-se clinicamente saudáveis, fazem uso do antiretroviral com monitorização contínua. Este é o primeiro relato que descreve o uso do raltegravir em gatos infectados naturalmente pelo FeLV e seus efeitos na carga viral circulante. Além disso, os pacientes descritos aqui foram acompanhados por um período maior que os trabalhos anteriores descritos." @default.
• W4308179007 created "2022-11-08" @default.
• W4308179007 creator A5005463726 @default.
• W4308179007 creator A5012301007 @default.
• W4308179007 creator A5045789053 @default.
• W4308179007 creator A5063394904 @default.
• W4308179007 creator A5065507133 @default.
• W4308179007 creator A5087074359 @default.
• W4308179007 date "2022-01-01" @default.
• W4308179007 modified "2023-10-04" @default.
• W4308179007 title "Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection" @default.
• W4308179007 cites W1509988813 @default.
• W4308179007 cites W1966898334 @default.
• W4308179007 cites W1980784581 @default.
• W4308179007 cites W1990321089 @default.
• W4308179007 cites W1991333230 @default.
• W4308179007 cites W1995380235 @default.
• W4308179007 cites W1998194593 @default.
• W4308179007 cites W1999297997 @default.
• W4308179007 cites W2007365807 @default.
• W4308179007 cites W2008733261 @default.
• W4308179007 cites W2010930029 @default.
• W4308179007 cites W2027801696 @default.
• W4308179007 cites W2033580461 @default.
• W4308179007 cites W2041595452 @default.
• W4308179007 cites W2066576784 @default.
• W4308179007 cites W2066787295 @default.
• W4308179007 cites W2101080301 @default.
• W4308179007 cites W2111368405 @default.
• W4308179007 cites W2111985786 @default.
• W4308179007 cites W2134826337 @default.
• W4308179007 cites W2140219252 @default.
• W4308179007 cites W2155368161 @default.
• W4308179007 cites W2329393410 @default.
• W4308179007 cites W2945796592 @default.
• W4308179007 cites W2947489730 @default.
• W4308179007 cites W3000318107 @default.
• W4308179007 cites W3016688393 @default.
• W4308179007 cites W3043604403 @default.
• W4308179007 cites W3132083162 @default.
• W4308179007 doi "https://doi.org/10.29374/2527-2179.bjvm003522" @default.
• W4308179007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36324639" @default.
• W4308179007 hasPublicationYear "2022" @default.
• W4308179007 type Work @default.
• W4308179007 citedByCount "1" @default.
• W4308179007 crossrefType "journal-article" @default.
• W4308179007 hasAuthorship W4308179007A5005463726 @default.
• W4308179007 hasAuthorship W4308179007A5012301007 @default.
• W4308179007 hasAuthorship W4308179007A5045789053 @default.
• W4308179007 hasAuthorship W4308179007A5063394904 @default.
• W4308179007 hasAuthorship W4308179007A5065507133 @default.
• W4308179007 hasAuthorship W4308179007A5087074359 @default.
• W4308179007 hasBestOaLocation W43081790071 @default.
• W4308179007 hasConcept C126322002 @default.
• W4308179007 hasConcept C142462285 @default.
• W4308179007 hasConcept C14430832 @default.
• W4308179007 hasConcept C159047783 @default.
• W4308179007 hasConcept C197934379 @default.
• W4308179007 hasConcept C203014093 @default.
• W4308179007 hasConcept C2522874641 @default.
• W4308179007 hasConcept C2777302000 @default.
• W4308179007 hasConcept C2779692357 @default.
• W4308179007 hasConcept C2779904517 @default.
• W4308179007 hasConcept C2780404665 @default.
• W4308179007 hasConcept C2993143319 @default.
• W4308179007 hasConcept C3013748606 @default.
• W4308179007 hasConcept C71924100 @default.
• W4308179007 hasConceptScore W4308179007C126322002 @default.
• W4308179007 hasConceptScore W4308179007C142462285 @default.
• W4308179007 hasConceptScore W4308179007C14430832 @default.
• W4308179007 hasConceptScore W4308179007C159047783 @default.
• W4308179007 hasConceptScore W4308179007C197934379 @default.
• W4308179007 hasConceptScore W4308179007C203014093 @default.
• W4308179007 hasConceptScore W4308179007C2522874641 @default.
• W4308179007 hasConceptScore W4308179007C2777302000 @default.
• W4308179007 hasConceptScore W4308179007C2779692357 @default.
• W4308179007 hasConceptScore W4308179007C2779904517 @default.
• W4308179007 hasConceptScore W4308179007C2780404665 @default.
• W4308179007 hasConceptScore W4308179007C2993143319 @default.
• W4308179007 hasConceptScore W4308179007C3013748606 @default.
• W4308179007 hasConceptScore W4308179007C71924100 @default.
• W4308179007 hasLocation W43081790071 @default.
• W4308179007 hasLocation W43081790072 @default.
• W4308179007 hasLocation W43081790073 @default.
• W4308179007 hasLocation W43081790074 @default.
• W4308179007 hasOpenAccess W4308179007 @default.
• W4308179007 hasPrimaryLocation W43081790071 @default.
• W4308179007 hasRelatedWork W1857359214 @default.
• W4308179007 hasRelatedWork W1987372627 @default.
• W4308179007 hasRelatedWork W1994770156 @default.
• W4308179007 hasRelatedWork W2022899561 @default.
• W4308179007 hasRelatedWork W2054227730 @default.
• W4308179007 hasRelatedWork W2060755150 @default.
• W4308179007 hasRelatedWork W2111368405 @default.
• W4308179007 hasRelatedWork W2152145664 @default.
• W4308179007 hasRelatedWork W2771197680 @default.
• W4308179007 hasRelatedWork W4308179007 @default.
• W4308179007 hasVolume "44" @default.

• next